Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Paclitaxel 2Irinotecan 2Carboplatin 2pertuzumab 1ledipasvir 1genexol-PM 1elbasvir-grazoprevir drug combination 1dolutegravir 1apatinib 1Vinorelbine 1Trastuzumab 1Tissue Banks 1Tai Ji 1Surgical Procedures, Operative 1Sofosbuvir 1S 1 (combination) 1Ritonavir 1Ribavirin 1Radiotherapy, Intensity-Modulated 1Qigong 1Physical Examination 1Oxaliplatin 1Nucleosides 1Nivolumab 1Magnesium 1Levoleucovorin 1Interleukin-2 1Immunotherapy 1Immune Checkpoint Inhibitors 1Hydralazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER_GOV × 4-fluorobenzoyl-TN-14003 × Clear all
NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Sheba Medical Center

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡